CN101415711A - 用于治疗香草素受体1相关病症的新的螺[咪唑烷-4,3’-吲哚]2,2’’,5’(1h)-三酮 - Google Patents

用于治疗香草素受体1相关病症的新的螺[咪唑烷-4,3’-吲哚]2,2’’,5’(1h)-三酮 Download PDF

Info

Publication number
CN101415711A
CN101415711A CNA2007800125819A CN200780012581A CN101415711A CN 101415711 A CN101415711 A CN 101415711A CN A2007800125819 A CNA2007800125819 A CN A2007800125819A CN 200780012581 A CN200780012581 A CN 200780012581A CN 101415711 A CN101415711 A CN 101415711A
Authority
CN
China
Prior art keywords
treatment
disease
pain
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800125819A
Other languages
English (en)
Chinese (zh)
Inventor
卡门·利昂
迈罗斯劳·托马斯泽夫斯基
西蒙·伍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101415711(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101415711A publication Critical patent/CN101415711A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CNA2007800125819A 2006-02-07 2007-02-06 用于治疗香草素受体1相关病症的新的螺[咪唑烷-4,3’-吲哚]2,2’’,5’(1h)-三酮 Pending CN101415711A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77111906P 2006-02-07 2006-02-07
US60/771,119 2006-02-07

Publications (1)

Publication Number Publication Date
CN101415711A true CN101415711A (zh) 2009-04-22

Family

ID=38345567

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800125819A Pending CN101415711A (zh) 2006-02-07 2007-02-06 用于治疗香草素受体1相关病症的新的螺[咪唑烷-4,3’-吲哚]2,2’’,5’(1h)-三酮

Country Status (21)

Country Link
US (2) US20070185179A1 (cg-RX-API-DMAC7.html)
EP (1) EP2013215A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009526043A (cg-RX-API-DMAC7.html)
KR (1) KR20080094906A (cg-RX-API-DMAC7.html)
CN (1) CN101415711A (cg-RX-API-DMAC7.html)
AR (1) AR059265A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007212786B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0707423A2 (cg-RX-API-DMAC7.html)
CA (1) CA2641632A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009000523A1 (cg-RX-API-DMAC7.html)
IL (1) IL192890A0 (cg-RX-API-DMAC7.html)
NO (1) NO20083547L (cg-RX-API-DMAC7.html)
NZ (1) NZ571070A (cg-RX-API-DMAC7.html)
RU (1) RU2421457C2 (cg-RX-API-DMAC7.html)
SA (1) SA07280027B1 (cg-RX-API-DMAC7.html)
SG (1) SG169387A1 (cg-RX-API-DMAC7.html)
TW (1) TW200801011A (cg-RX-API-DMAC7.html)
UA (1) UA93226C2 (cg-RX-API-DMAC7.html)
UY (1) UY30132A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007091947A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806407B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409746A (zh) * 2018-05-15 2018-08-17 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921576B2 (en) 2011-10-19 2014-12-30 Kowa Company, Ltd. Spiroindoline compound, and medicinal agent comprising same
TWI586668B (zh) * 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
ZA806623B (en) * 1979-11-13 1981-12-30 Ici Ltd Substituted indoline-2-one derivatives
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
GB8331194D0 (en) 1982-12-20 1983-12-29 Ici Plc Chemical process
US4611062A (en) * 1984-03-26 1986-09-09 Imperial Chemical Industries Plc Process for resolving certain spiro compounds
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
JP2003505388A (ja) * 1999-07-21 2003-02-12 アストラゼネカ・アクチエボラーグ 新規化合物
US7248802B2 (en) 2002-11-27 2007-07-24 Nokia Corporation Distribution of a synchronization signal in an optical communication system
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
SE0301446D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
AU2004247559B2 (en) 2003-06-12 2009-08-27 Astellas Pharma Inc. Benzamide derivative or salt thereof
GB0326633D0 (en) * 2003-11-14 2003-12-17 Merck Sharp & Dohme Therapeutic agents
JP2008508190A (ja) 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
WO2007091948A2 (en) 2006-02-07 2007-08-16 Astrazeneca Ab Novel spiro [imidazolidine-4, 3´-indole] 2, 2´,5´(1h) triones for treatment of conditions associated with vanilloid receptor 1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409746A (zh) * 2018-05-15 2018-08-17 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法
CN108409746B (zh) * 2018-05-15 2021-08-24 中山大学 一种含吡咯或吲哚并氮杂环烷结构的手性氧代螺环吲哚类化合物及其消旋体和制备方法

Also Published As

Publication number Publication date
AR059265A1 (es) 2008-03-19
AU2007212786B2 (en) 2011-06-02
WO2007091947A3 (en) 2007-10-04
US7868181B2 (en) 2011-01-11
IL192890A0 (en) 2009-02-11
EP2013215A4 (en) 2010-09-08
UA93226C2 (en) 2011-01-25
EP2013215A2 (en) 2009-01-14
KR20080094906A (ko) 2008-10-27
AU2007212786A1 (en) 2007-08-16
ZA200806407B (en) 2009-04-29
JP2009526043A (ja) 2009-07-16
BRPI0707423A2 (pt) 2011-05-03
TW200801011A (en) 2008-01-01
NZ571070A (en) 2011-07-29
US20090137650A1 (en) 2009-05-28
WO2007091947A2 (en) 2007-08-16
UY30132A1 (es) 2009-07-17
CA2641632A1 (en) 2007-08-16
SG169387A1 (en) 2011-03-30
RU2421457C2 (ru) 2011-06-20
SA07280027B1 (ar) 2010-11-22
RU2008131905A (ru) 2010-03-20
NO20083547L (no) 2008-11-05
CL2009000523A1 (es) 2009-07-17
US20070185179A1 (en) 2007-08-09
AU2007212786A8 (en) 2010-05-06
WO2007091947A8 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
AU2009247262B2 (en) Amide compound
JP4667384B2 (ja) イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
CN101415713A (zh) 用于治疗香草素受体1相关病症的新螺[咪唑烷-4,3’-吲哚]-2,2’,5(1’h)-三酮
CN110121343B (zh) 用作gpr120调节剂的双环化合物
AU2012292036A1 (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
CN116354901B (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
SK17172002A3 (sk) Deriváty 3-azabicyklo[3,1,0]hexánu vykazujúce afinitu k opiátovým receptorom
JP2009521431A (ja) バニロイド受容体1(vr1)阻害剤としての新規なベンゾイミダゾール誘導体
CN104520304B (zh) 咪唑并[2,1‑b]噻唑衍生物、其制备及作为药物的用途
CN112888674B (zh) 多环化合物作为可溶性环氧化物水解酶抑制剂
US7868181B2 (en) Compounds
US7714010B2 (en) Pyrrolobenzimidazolones and their use as anti-proliferative agents
JP5297386B2 (ja) 5−アルキルオキシ−インドリン−2−オン誘導体、これらの調製およびv2バソプレシン受容体の選択的リガンドとしての治療におけるこれらの応用
KR20150070290A (ko) Trp 채널 길항제로서의 6-아미노인돌 유도체
CN116082259B (zh) 氨基甲酸酯基或氨甲酰基取代的5-ht2b拮抗剂
TWI454470B (zh) 硫苯並薁丙酸衍生物之製造法
CN101268062A (zh) 对gaba-b-受体具有亲合性的2-羟基-丙酸衍生物和3-羟基-苯并呋喃-2-酮衍生物
MX2008009999A (es) Novedosos espiro[imidazolidina-4,3'-indol]-2,2',5(1'4)-triones para tratamiento de condiciones asociadas con receptor 1 vaniloide
JP2006117667A (ja) 3−アリール−3−メチル−キノリン−2,4−ジオン化合物、その製造方法及びそれを含む製薬組成物
CN106946759A (zh) 2‑吲哚酮衍生物及其开环衍生物及合成方法与用途
CN101415712A (zh) 螺[咪唑烷-4,3’-吲哚]2,2’,5’(1h)三酮在治疗与香草素受体1有关的疾病中的用途
WO1999035142A1 (en) 4-(3-indolyl)imidazole derivatives
HK40052677A (en) Polycyclic compounds as soluble epoxide hydrolase inhibitors
HK1132273B (en) 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
HK1132273A1 (en) 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090422